Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins

Cardiovascular Diabetology

Volumn 5, Issue , 2006, Pages

  Tenenbaum, Alexander ^a,b,c   Fisman, Enrique Z ^b,c   Motro, Michael ^c   Adler, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIPIZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRIPHASIC CONTRACEPTIVE AGENT; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FLUSHING; GASTROINTESTINAL TOXICITY; GLUCOSE METABOLISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; INTERMITTENT CLAUDICATION; LIPID BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PLEIOTROPY; REGULATORY MECHANISM; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; NIACIN;

EID: 33749536035     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-5-20     Document Type: Review

References (78)

1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC; National Heart, Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-504.
3. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
5. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
6. Fisman EZ, Adler Y, Tenenbaum A: Statins research unfinished saga: desirability versus feasibility. Cardiovasc Diabetol 2005, 41:8.
7. Christopher CP: The IDEAL cholesterol: lower is better. JAMA 2005, 294:2492-2494.
8. Pitt B: Low-density lipoprotein cholesterol in patients with stable coronary heart disease - is it time to shift our goals? N Engl J Med 2005, 352:1483-1484.
9. Tenenbaum A, Fisman EZ: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc Diabetol 2004, 3:10.
10. Sacks FM, for the Expert Group on HDL Cholesterol: The role of high-density lipoprotein [HDL] cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol 2002, 90:139-143.
11. Fruchart JC: Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001, 88(12A):24N-29N.
12. Verges B: Clinical interest of PPARs ligands. Diabetes Metab 2004, 30:7-12.
13. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
14. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
15. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)). Am J Cardiol 1997, 8:1125-1129.
16. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998, 21:641-648.
17. Meade T, Zuhrie R, Cook C, Cooper J: Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002, 325(7373):1139.
18. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
19. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001, 357:905-910.
20. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
21. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
22. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
23. Tenkanen L, Manttari M, Kovanen P, Virkkunen H, Manninen V: Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006, 166:743-748.
24. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
25. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
26. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
27. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14.
28. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741.
29. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
30. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
31. Bloomfield HE: The role of fibrates in a statin world. Arch Intern Med 2006, 166:715-716.
32. Groop LC: Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999:S1-S7.
33. Tenenbaum A, Fisman EZ, Motro M: Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol 2003, 2:4.
34. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J. Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
35. Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001, 3:83-92.
36. Rovellini A, Sommariva D, Branchi A, Maraffi F, Montalto C, Gandini R, Fasoli A: Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res 1992, 25:237-245.
37. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N,Ckumura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001, 50:477-480.
38. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002, 112:275-280.
39. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990, 13:855-863.
40. Despres JP, Lemieux I, Robins SJ: Role of fibric Acid derivatives in the management of risk factors for coronary heart disease. Drugs 2004, 64:2177-2198.
41. Jin FY, Kamanna VS, Kashyap, ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-1 but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020-2028.
42. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004, 45:1835-1845.
43. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9:352-355.
44. The Coronary Drug Project Research Group: The Coronary Drug Project: Design, Methods, and Baseline Results. Circulation 1973, 47:1-50.
45. Canner PL, Furberg CD, McGovern ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006, 97:477-479.
46. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
47. Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ: The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006, 6:571-587.
48. McCormack PL, Keating GM: Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005, 65:2719-2740.
49. Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990, 264:723-726.
50. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ: Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000, 14:567-572.
51. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV: Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 2003, 52:699-704.
52. Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005, 95:1309-1313.
53. Shepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, Lawrie TD: The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 1979, 33:433-444.
54. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365-374.
55. Insull W Jr: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006, 99:257-273.
56. Toth PP, Davidson MH: Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:455-462.
57. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
58. Davis HR Jr, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:2032-2038.
59. Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ: Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease? Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:481-488.
60. Schaefer EJ, Asztalos BF: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 2006, 17:394-398.
61. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
62. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
63. Robins SJ: Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol 2003, 14:575-583.
64. Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ: Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol 2004, 97:167-172.
65. Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004, 6:148-157.
66. Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin 2004, 20:241-247.
67. Tenenbaum A, Fisman EZ, Motro M: Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims. J Clin Endocrinol Metab 2004, 89:1978.
68. Robins SJ, Bloomfield HE: Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006, 17:431-439.
69. Verges B: Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol 2005, 16:648-651.
70. Jokubaitis LA: Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract 1996:28-32.
71. Gavish D, Leibovitz E, Shapira I, Rubinstein A: Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000, 247:563-569.
72. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active Iovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001, 69:340-345.
73. Beggs PW, Clark DW, Williams SM, Coulter DM: A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). Br J Clin Pharmacol 1999, 47:99-104.
74. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L: Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003, 92:794-797.
75. Farnier M: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003, 3:169-178.
76. Shek A, Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother 2001, 35:908-917.
77. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
78. Toth PP, Davidson MH: Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 2005, 6:131-139.